pharmaceutical

Grifols makes net profit of €133.5 million in the first half of 2012

July 31, 2012 07:42 PM | CNA / David Tuxworth

The Catalan pharmaceutical company Grifols, the third world leader in the production of blood plasma based technologies, has seen its turnover increase by 15% in the first half of 2012 to €1.32 billion. Its net profit for the first half of 2012 was €133.5 million, seven times that of the previous year. The company’s success is attributed to its wide geographical consumer base and the recent purchase of US based Talecris Plasma Resources.

Grifols strengthens its presence in the Chinese market

May 22, 2012 03:33 PM | CNA / Laura Quintana

The Catalan pharmaceutical company Grífols, third worldwide company in plasma derivatives, has signed a cooperation agreement with the Shanghai Blood Bank. The agreement, which strengthens the presence of the Catalan company in China, promotes blood genotyping research. The Chinese institution will use the Grifols’ genetic test BLOODchip in transfusion compatibility studies. Shanghai Blood Bank serves over 20 million people and receives more than 300.000 donations per year. In 2011, Grifols sales in China grew by 30%.

Catalan Mesoestetic Pharma Group exports 85% of its production and is present in 62 markets worldwide

May 19, 2012 12:18 AM | CNA / Bertran Cazorla

The Catalan company Mesoestetic has built a new factory that multiplies by ten its previous facilities. Furthermore, the company will increase its staff by 30%. The Catalan Minister for Business and Employment has praised the company as a model for innovation and internationalisation. He has spoke of the long tradition of the pharmaceutical industry in Catalonia as well as the Catalan economy’s export capacity.

Pfizer to invest more than 6 million euros in their Catalan plant, “a worldwide reference” in vaccines for animals

June 7, 2011 12:14 AM | CNA / Lourdes Casademont / Marc Navarro

The factory will increase its output of biological and pharmaceutical products by 40% over 3 years, taking work from closing factories in Europe and the United States. The Catalan plant is specialised in animal health and vaccines for livestock. It was bought in 2009 by the North American pharmaceutical giant, in a small town near Girona.